Overcoming Barriers to Treatment-Free Remission (TFR) in Chronic Myeloid Leukemia (CML): Predictive Factors, Patient Selection, and Emerging Strategies to Expand Eligibility
Treatment-free remission (TFR) has become an important therapeutic goal for patients with chronic myeloid leukemia (CML) who achieve a sustained deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. However, only a subset of eligible patients maintain durable remission after discontinuation, and man...